TNFα Blockade Overcomes Resistance to Anti-Pd-1 in Experimental Melanoma

Nature Communications - United Kingdom
doi 10.1038/s41467-017-02358-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Non-Classical Estrogen Signaling Inhibits Melanoma and Improves Response to PD-1 Blockade

SSRN Electronic Journal
2018English

Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy

Clinical Cancer Research
Cancer ResearchOncology
2017English

CTLA4 Methylation Predicts Response to Anti–PD-1 and Anti–CTLA-4 Immunotherapy in Melanoma Patients

JCI insight
Medicine
2018English

Safety and Tumor Responses With Lambrolizumab (Anti–PD-1) in Melanoma

New England Journal of Medicine
Medicine
2013English

Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/P53 Mutant Lung Cancer

Cancers
Cancer ResearchOncology
2019English

Poor Outcome With Anti-Programmed Death-Ligand 1 (PD-L1) Antibody Due to Poor Pharmacokinetic Properties in PD-1/PD-L1 Blockade-Sensitive Mouse Models

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2020English

823 Biomarker Approaches for Anti-Pd-1 in Melanoma: A Meta-Analysis

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Can IDO Activity Predict Primary Resistance to Anti-Pd-1 Treatment in NSCLC?

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2018English

Circulating Tumour DNA for Monitoring Treatment Response to Anti-Pd-1 Immunotherapy in Melanoma Patients

Acta Dermato-Venereologica
DermatologyMedicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy